THE US Food and Drug Administration (FDA) has approved the first pharmaceutical product containing cannabidiol.
The product is called Epidiolex and is approved for seizures associated with Lennox-Gastaut and Dravet Syndromes
The FDA approval highlighted necessity of controlled clinical studies, uniformity of drug quality and consistent delivery, as well as intent to take action against non-FDA approved CBD containing product.
ASX-listed medicinal cannabis dermatology company Botanix has welcomed the approval.
Cannabidiol is the drug that Botanix utilizes in its acne, atopic dermatitis and other pipeline dermatology products.
An approval by FDA that cannabidiol is safe and effective (even for a disease such as epilepsy which is not being pursued by Botanix), provides a positive reference basis for Botanix's FDA approval applications, that did not exist previously.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jun 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jun 18
